Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01487174 · ClinicalTrials.gov registry record · Phase 3
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
A Phase 3 study, sponsored by Kadmon Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT01487174: Clinical Trial Phase 3 study, sponsored by Kadmon Corporation.
NCT01487174 is a Phase 3 study that was terminated before completion, run by Kadmon Corporation. The registered enrollment target is 8 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01487174, a Phase 3 study, was terminated before completion, sponsored by Kadmon Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung cancer (NSCLC) who have progressed after first- or second- line chemotherapy. It is hypothesized that KD019 can prolong survival compared with erlotinib.
Interventions
- DRUG Erlotinib
- DRUG KD019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2011-12-14 |
| Est. Completion | 2013-07-25 |
| Phase | Phase 3 |
Why NCT01487174 stopped before completion
NCT01487174 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT01487174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01487174 about?
NCT01487174 is a clinical study titled "KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy". This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung cancer (NSCLC) who have progressed after first- or second- line chemotherapy. It is hypothesized that KD019 can prolong survival compared with erlotinib.
What is the current status of trial NCT01487174?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2011-12-14. Estimated completion is 2013-07-25.
What interventions are being tested in trial NCT01487174?
The interventions under investigation include: Erlotinib (DRUG), KD019 (DRUG).
Who is sponsoring clinical trial NCT01487174?
This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01487174's enrollment target sits among peer trials
8 1993rd of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI